The drug also delivered a disease control rate (DCR) of 83.3% in high-dose cohorts and a mean progression-free survival of 6.3 months in SCLC patients
The company reported free cash flow of Rs. 2,590 Mn for FY26
The deal also establishes a new subsidiary, Excellos Labs, which will oversee continued operations in San Diego
The global pharmaceutical company has been featured in both the DJBIC World Index and the DJBIC Emerging Markets Index
Access to genomic testing, not therapy cost, is the biggest challenge
New Delhi facility expands Lupin’s specialized neuro-rehabilitation network after Mumbai and Hyderabad launches
US formulations grew 11% to Rs. 564 crore as Alembic enters US branded pharmaceuticals market with launch of Pivya
FY26 revenue rises to Rs. 4,359 crore as India’s leading CDMO strengthens global footprint with EU GMP certifications, UK MHRA approval and Europe supplies
Nationwide preventive health initiative aims to make cardiovascular screening at age 30 a standard healthcare milestone
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
